iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders

Hideyuki Okano, Satoru Morimoto

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and therapeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease.

本文言語English
ページ(範囲)189-208
ページ数20
ジャーナルCell stem cell
29
2
DOI
出版ステータスPublished - 2022 2月 3

ASJC Scopus subject areas

  • 分子医療
  • 遺伝学
  • 細胞生物学

フィンガープリント

「iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル